Steven Phillips, MD
Steven Phillips, MD is a Yale-trained physician and co-author of the book, “Chronic: The Hidden Cause of the Autoimmune Pandemic”. He has treated over 20,000 patients from over 20 countries. Dr. Phillips is well-published in peer-reviewed medical literature such as the Lancet and has been featured in popular media such as the NY Times, the Huffington Post, Dr. Oz, Fox’s Lyme and Reason, CBS, Revolution Health Radio with Chris Kresser, Dr. Been, and The Doctors. Ticktective Video and Podcast Editor: Kiva Schweig.
Miss California USA 2020 and Bay Area Lyme Ambassador, Allyshia Gupta, shares her personal story of finding herself through hardship and loss, and the importance of service as a source of strength. Ticktective Video and Podcast Editor: Kiva Schweig.
Wendy Adams, MBA
Wendy Adams, MBA, Bay Area Lyme Advisory Board Member and Research Grant Director, discusses Lyme research, Lyme persistence studies, and the reality of Lyme rashes. Ticktective Video and Podcast Editor: Kiva Schweig.
FOR IMMEDIATE RELEASE
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com
Bay Area Lyme Foundation Launches Ticktective™ Podcast
PORTOLA VALLEY, Calif., September 30, 2020 — Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces the launch of the Ticktective podcast and video series. Ticktective is a Bay Area Lyme Foundation program designed to investigate the latest scientific knowledge and advances in Lyme and tick-borne diseases. The podcast offers insightful discussion with researchers, physicians, patients, and thought leaders in the field.
“Because the science surrounding tick-borne disease is so complex and there are so many unanswered questions, Ticktective aims to share firsthand perspectives about the challenges of Lyme in ways that will intrigue more scientists, physicians and patients to join our battle towards making Lyme disease easy to diagnose and simple to cure,” said Linda Giampa, executive director, Bay Area Lyme Foundation.
There are more than 400,000 people diagnosed with Lyme disease each year in the US, and millions of Americans live with persistent Lyme disease (PLD) caused by an ongoing bacterial infection. The current “gold standard” diagnostic for Lyme disease misses up to 60% of cases of early stage Lyme disease, and if not treated promptly, Lyme may progress to a debilitating stage, becoming difficult, or impossible, to cure. Bay Area Lyme Foundation has funded over 100 research projects at 37 institutions across the US in a mission to find solutions for these patients.
Bay Area Lyme Foundation Advisory Board Member, “Chronic” co-author and SonyATV singer/songwriter, Dana Parish, shares her perspective on chronic diseases, autoimmunity, COVID-19, and speaking out in the face of adversity. “Chronic: The Hidden Cause of the Autoimmune Pandemic and How to Get Healthy Again” is available for purchase on Amazon here. Ticktective Video and Podcast Editor: Kiva Schweig.
Jacob Lemieux, MD, PhD
Bay Area Lyme’s 2020 Emerging Leader Award Winner, Jacob Lemieux, MD, PhD, of the Harvard/MIT Broad Institute, discusses Borrelia and malaria, next-generation sequencing, COVID-19, and Lyme diagnostic challenges. Ticktective Video and Podcast Editor: Kiva Schweig.
Artem Rogovsky, DVM, PhD
Bay Area Lyme’s 2020 Emerging Leader Award Winner, Artem Rogovsky, DVM, PhD, of the Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, discusses radioactive ticks, Lyme diagnostics, and how a kid’s birthday party can lead to novel research. Ticktective Video and Podcast Editor: Kiva Schweig.
Liz Horn, PhD, MBI
Principal Investigator for the Bay Area Lyme Disease Biobank, Liz Horn, PhD, MBI, discusses the Biobank which has enrolled over 900 participants, supporting over 50 research projects so far. They support research projects across the nation by providing precious serum, whole blood, urine and tissue samples to researchers. Ticktective Video and Podcast Editor: Kiva Schweig.
– Wendy Adams, Research Grant Director, Bay Area Lyme Foundation
This pandemic has brought many different modalities in diagnostics, drug development and vaccines to the popular press. In the Tick-borne Disease (TBD) community, we have seen the issues that arise when the timely diagnosis and treatment of infectious disease are hampered by insensitive diagnostics and ineffective treatments.
It bears repeating however, that drugs that fight the infection in question (antibiotics, antiparasitics, or antivirals) are a large part of any eventual solution to an outbreak, especially in advance of a vaccine (see HIV). Antimicrobial therapeutics help keep the pathogen from replicating uncontrolled, allowing the complicated immune system processes to catch up to it, control it and then eradicate it.
One specific treatment modality is being widely discussed: monoclonal antibodies (mAbs). These are the drugs upon which the whole biotech industry and companies like Genentech, Biogen and Amgen were literally built. Six out of the top 10 drugs by sales are mAbs, mostly for oncology and autoimmune disease indications. However, mAbs have not been commonly used for infectious disease (with one major exception we’ll talk about later).
What are monoclonal antibodies? How do they work?
Antibodies are proteins made by the mammalian immune system. They are a workhorse of the acquired immune response and fight specific antigens, which can be anything from an invading pathogen to an aberrant cell or cytokine that needs destruction. Monoclonal antibodies as a drug class are also very specific and only bind to one antigen. They can bind to a single receptor on the outside of a cell, so that cell can’t receive or send out a message. Or the cell can be tagged so the immune system recognizes the cell as foreign and can destroy it. Binding only one target is important to reduce side effects caused by binding to multiple targets.